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Background. (Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients. 
Host genetic determinants of response are therefore in demand.
Methods. In this genome-wide association study (GWAS), CHB patients, treated with (Peg)IFN for at least 12 weeks ± nucle-
os(t)ide analogues within randomized trials or as standard of care, were recruited at 21 centers from Europe, Asia, and North 
America. Response at 24 weeks after (Peg)IFN treatment was defined as combined hepatitis B e antigen (HBeAg) loss with hepatitis 
B virus (HBV) DNA <2000 IU/mL, or an HBV DNA <2000 IU/mL for HBeAg-negative patients.
Results. Of 1144 patients, 1058 (92%) patients were included in the GWAS analysis. In total, 282 (31%) patients achieved the 
response and 4% hepatitis B surface antigen (HBsAg) loss. GWAS analysis stratified by HBeAg status, adjusted for age, sex, and the 
4 ancestry components identified PRELID2 rs371991 (B= −0.74, standard error [SE] = 0.16, P = 3.44 ×10–6) for HBeAg-positive 
patients. Importantly, PRELID2 was cross-validated for long-term response in HBeAg-negative patients. G3BP2 rs3821977 (B = 1.13, 
SE = 0.24, P = 2.46 × 10–6) was associated with response in HBeAg-negative patients. G3BP2 has a role in the interferon pathway and 
was further examined in peripheral blood mononuclear cells of healthy controls stimulated with IFNα and TLR8. After stimulation, 
less production of IP-10 and interleukin (IL)-10 proteins and more production of IL-8 were observed with the G3BP2 G-allele.
Conclusions. Although no genome-wide significant hits were found, the current GWAS identified genetic variants associated 
with (Peg)IFN response in CHB. The current findings could pave the way for gene polymorphism-guided clinical counseling, both 
in the setting of (Peg)IFN and the natural history, and possibly for new immune-modulating therapies.
clinical Trials Registation: NCT01401400.
Keywords. peginterferon; chronic hepatitis B; response; GWAS; genetics.
Approximately 250 million people worldwide have evidence of 
a chronic hepatitis B (CHB) infection, which may progress to 
liver cirrhosis, liver decompensation, hepatocellular carcinoma 
(HCC), and death. The aim of antiviral therapy is to improve 
the quality of life and the long-term prognosis [1–3]. Current 
internationally recommended treatments Tenofovir, Entecavir, 
and (pegylated) interferon ([Peg]IFN), which can reduce viral 
load and hepatic necroinflammation, decrease the risk of HCC 
and complications of cirrhosis [4–6]. (Peg)IFN has both direct 
antiviral and immune modulating effects. The main advantages 
of this agent include a finite course of treatment and the lack 
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of drug resistance. It leads to an improved prognosis and high 
rates of hepatitis B surface antigen (HBsAg) loss during long-
term follow-up in those with a favorable response [7]. However, 
it requires subcutaneous injections and carries considerable 
side effects. In addition, only 20–30% of treated patients have a 
sustained response to treatment [8–11]. It is therefore import-
ant to identify host genetic determinants of response to reduce 
the costs and side effects of treatment and make this treatment 
modality more acceptable to patients. Genetic host studies on 
response to (Peg)IFN provide substantial knowledge on the 
interaction between the host and the virus to induce immune 
control, both for immune modifying therapy and the natural 
history of disease. Numerous small studies conducted with 
selected single-nucleotide polymorphism (SNP) have shown 
associations with (Peg)IFN response; however, to date, a large 
genome-wide association study (GWAS) to predict the response 
to (Peg)IFN in CHB patients has not been performed. Causal 
or regulating SNPs in genes modifying the immune response 
can be identified through a GWAS and can be used to assess the 
chance of response to treatment and select patients who have 
a high probability of response to (Peg)IFN. This would poten-
tially pave the way for further functional follow-up and clinical 
validation on gene polymorphisms-guided therapeutic strati-
fication, both in the setting of (Peg)IFN and possibly for new 
therapeutic agents.
PATIENTS AND METHODS
Patients
In this investigator-initiated multicentre global GWA study, 
CHB patients treated with PegIFN alpha or conventional inter-
feron α (IFN α) within randomized controlled trials, prospec-
tive cohort studies, or as part of standard of care at 21 tertiary 
care centers from Europe, Asia, and North America were ini-
tially eligible for inclusion. The inclusion and exclusion criteria 
for the trials are described elsewhere [7, 8, 10, 12–22]. For the 
current study, the minimal duration of therapy was 12 weeks. 
Patients who received combined treatment of PegIFN and 
nucleos(t)ide analogues (NA) or ribavirin therapy were also 
included, because combination treatment with these agents 
does not influence response rates at 6 months post-treatment 
as compared to PegIFN alone [7–11, 13, 16, 17, 23]. PegIFN 
add-on therapy to short-term [12] or long-term [14, 20–22] NA 
treatment was also allowed. Patients were excluded in case of a 
hepatitis C, hepatitis delta, or human immunodeficiency virus 
coinfection. An overview of the origin of included patients can 
be found in Supplementary Table 1. The study was conducted 
in agreement with the guidelines of the Declaration of Helsinki 
and the principles of Good Clinical Practice. The study was 
approved by the ethics committee of each participating centre. 
All patients gave written informed consent according to stan-
dards of the local ethics committees at each of the participating 
centres. All authors had access to the study data and reviewed 
and approved the final manuscript. The study protocol can be 
accessed at clinicaltrials.gov, identifier NCT01401400.
Endpoints
The primary endpoint was assessed at 24 weeks post (Peg)
IFN treatment, and the primary response was defined 
as combined hepatitis B e antigen (HBeAg) loss with a 
hepatitis B virus (HBV) DNA <2000 IU/mL for HBeAg-
positive patients, and an HBV DNA level <2000 IU/mL 
for HBeAg-negative patients, including confirmed HBsAg 
loss, according to standard definitions reported by clini-
cal practice guidelines [1–3]. Other endpoints considered 
were sustained response (ie, patients with both response at 
24 weeks post-(Peg)IFN and at end of follow-up) and end 
of follow-up response (ie, includes patients who achieved 
response during follow-up, but excluding those who lost 
response). Combination of the primary endpoint with ALT 
normalization was considered as well and can be found in 
the Supplementary Materials.
DNA Extraction, Host Genotyping, and Laboratory Measurements
These data can be found in the Supplementary Materials.
Genome-wide Association and Statistical Analysis
Data were analyzed according to genetic analysis populations 
(GAP). Patients included in the GAP comprise all patients 
in the study who were successfully genotyped (ie, passed the 
quality control steps) and were treated with (Peg)IFN for at 
least 12 weeks. In this analysis, if data on outcome were miss-
ing, patients were not considered in the analysis. GAP analy-
sis was applied both for the primary as well as the secondary 
endpoints. For each genotyped or imputed SNP, binary logis-
tic regression analysis of the primary response was performed 
with additive SNP effects for the total cohort with adjustment 
for sex, age, baseline HBeAg status, and 4 ancestry principal 
components (PCs). These PCs represent the genetic ethnicity, 
which are extracted from the genetic data. Next to a GWAS 
for the total cohort, we performed a stratified GWAS by 
HBeAg status as well, because patients with HBeAg-negative 
CHB may be a more genetically selected subgroup and there-
fore possibly biologically different compared to those with 
HBeAg-positive CHB [1–3]. RVtests were used for the GWAS 
analysis [24]. With RVtests, dosage information was used 
instead of best-guess genotypes. Moreover, all variants with 
a minor allele frequency <1% were discarded. Finally, with 
RVtests, the Wald test was used to determine significance 
[24]. A P-value of less than 5 × 10–8 was considered genome-
wide significant. Q-Q plots were generated to inspect the 
consistency between the resultant and expected test statistics 
(ie, any evidence of genomic inflation), and genomic control 
was applied to adjust for any residual inflation.
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Sensitivity Analyses
We performed a multivariable analysis including the 
obtained SNPs of interest, additionally adjusted for the 
duration of (Peg)IFN treatment, HBV DNA load and ALT 
at baseline. Moreover, a sensitivity analysis for the combi-
nation of the primary endpoint with ALT normalization, 
a stratified analysis by physician-reported ethnicity, and 
an analysis for the treatment regimen received were per-
formed. Finally, a review of previously described SNPs 
associated with (PEG)IFN response was performed. All 
sensitivity analysis can be found in the Supplementary 
Materials.
RESULTS
Patient Characteristics
In total, 1695 patients treated with (Peg)IFN were identified at 
21 centers worldwide. The patient selection can be found in the 
study workflow (Figure 1). After selection procedures, a GWAS 
attempt could be made on 1144 (67%) of which 1058 (92%) were 
successfully included in the GWAS cohort after quality control 
checks (Table 1). In sum, 534 (51%) patients were treated as part 
of (randomized) trials or per study protocols, and 524 (50%) 
patients were treated as part of standard of care [7, 8, 10, 12–22] 
(Supplementary Materials). In total, 923 patients were analyzed 
per GAP for the primary endpoint.
Primary Outcome and Follow-up
Per GAP analysis, 282 (31%) out of 923 patients achieved 
the primary response (12% with HBsAg loss, 4% of the GAP 
cohort). The primary response rate for white patients was 22% 
(60/278), and 34% (217/636) for Asians. For HBeAg-positive 
patients the primary response rate was 24% (121/509) and for 
HBeAg-negative patients 39% (161/414). Patients were followed 
for a median of 146 weeks (interquartile range [IQR] 96–401) 
from baseline, which was a median of 99 weeks (IQR 48–353) 
from cessation of (Peg)IFN treatment.
Figure 1. Study workflow for both samples and single-nucleotide polymorphisms. Abbreviations: GWAS, genome-wide association study; HDV, hepatitis Delta virus 
infection; HWE, Hardy-Weinberg equilibrium; IFN, interferon; ITT, intention-to-treat analysis; MAF, minor allele frequency; PI, PI-HAT, variable calculated by PLINK from the 
identify-by-state (IBS) matrix; SNPs, single-nucleotide polymorphisms. aNot excluded from analysis.
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Genome-wide Association Analysis
First, a GWAS was performed for the complete cohort (GAP 
n  =  923) adjusted for sex, age, 4 ancestry principal compo-
nents, and baseline HBeAg status. The Q-Q plot is shown in 
Figure 2. There were no genome-wide significant associa-
tions, but 3 suggestive loci (P < 5.0 × 10–6) were found (Table 
2 and Supplementary Table 2). Of these, rs78900671 GC allele 
(TRAPPC9, COL22A1) had the strongest association (response 
of best-guess genotypes GG vs GC 28.4% vs 59%; additive 
model β = 1.434, standard error [SE] = 0.29, P = 6.43 × 10–7). 
Figure 3 shows the Manhattan plot; for the suggestive loci, 
zoomed-in versions of the Manhattan plot are illustrated in the 
Supplementary Materials. Moreover, both a sensitivity analysis 
and a look-up of previously described SNPs can be found in the 
Supplementary Materials as well.
Genome-wide Association Analysis Stratified by Baseline HBeAg Status
A subgroup specific GWAS was performed stratified by HBeAg 
status with adjustment for sex, age, and 4 ancestry principal com-
ponents. For both groups there were no genome-wide significant 
associations, but suggestive loci were identified (P < 5.0 × 10–6). 
The Q-Q and Manhattan plots are shown in Figures 2 and 3.
For HBeAg-positive patients, rs371991 on chromosome 5 
(PRELID2) was associated with the primary outcome (additive 
Table 1. Patient Characteristics According to Hepatitis B e Antigen Status at Baseline
Characteristics All Patients (n = 1058) HBeAg-positive (N = 549) HBeAg-negative (N = 509)
Demography
 Mean (SD) age, years 39 (11) 35 (10) 43 (10)
 Male, n (%) 753 (71%) 374 (68%) 379 (75%)
Reported ethnicitya    
 Asian 646 (61%) 429 (78%) 217 (43%)
 White 375 (35%) 101 (18%) 274 (54%)
 African/other 37 (3%) 19 (4%) 18 (3%)
Previous IFN therapy, n (%) 88 (8%) 36 (7%) 52 (10%)
Therapy allocation, n (%)    
 PegIFN monotherapy 551 (52%) 254 (46%) 297 (58%)
 PegIFN + NA 239 (23%) 140 (26%) 99 (20%)
 PegIFN add-on 90 (9%) 86 (16%) 4 (1%)
 IFN ± NA 156 (15%) 69 (12%) 87 (17%)
 PegIFN + Ribavirin 22 (2%) 0 22 (4%)
 Duration of (Peg)IFN, weeks 49 (18) 44 (14) 55 (20)
  (Peg)IFN as part of study/trial 534 (51%) 308 (56%) 226 (44%)
Laboratory results, mean (SD)    
 ALT (U/L)b 2.9 (3.0) 3.0 (2.9) 2.8 (3.0)
 HBV DNA, log IU/mL 5.7 (2.2) 6.4 (2.2) 5.0 (1.9)
 HBsAg, log IU/mLc 3.5 (1.0) 3.7 (1.0) 3.2 (0.8)
HBV genotype, n (%)d    
 A 59 (6%) 35 (6%) 24 (5%)
 B 78 (7%) 40 (7%) 38 (8%)
 C 196 (19%) 102 (19%) 94 (19%)
 D 195 (18%) 46 (8%) 149 (29%)
 Other 23 (2%) 10 (2%) 13 (3%)
Liver cirrhosis 79 (8%) 26 (5%) 53 (10%)
Long-term follow-up    
 Weeks from baseline, median (IQR) 146 (96–401) 144 (77–384) 188 (120–418)
 Weeks from EOT, median (IQR) 99 (48–353) 96 (32–347) 135 (72–366)
Primary response GAP, n (%)    
 At 24 weeks post IFN 282/923 (31%) 121/509 (24%) 161/414 (39%)
 At end of follow-up 261/1028 (25%) 115/534 (22%) 146/494 (30%)
 Sustained responsee 196/902 (22%) 94/497 (19%) 102/405 (25%)
Liver cirrhosis was based on pathology or radiology ± clinical characteristics or the combination of these.
Abbreviations: base, baseline (start (Peg)IFN treatment); EOT, end of treatment; GAP, genetic analysis populations; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; IFN, interferon; IQR, 
interquartile range; NA, nucleos(t)ide analogue; SD, standard deviation.
aReported ethnicity by local investigator. This does not resemble the ethnicity based on genetics (ancestry principal components) used in the genome-wide association study (GWAS) 
analyses.
bMultiples of upper limit of the normal range. 
c315 (30%) missing.
d507 (48%) missing.
eSustained response was defined as patients with response both at 24 weeks post IFN and at end of follow-up. 
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β = −0.74, SE = 0.16, P = 3.44 ×10–6, Table 2). Response rates for 
best-guess genotypes were 38%, 23%, and 13% for AA, AG, and 
GG, respectively (Figure 4). As a sensitivity analysis, a multi-
variable analysis additionally adjusted for the duration of (Peg)
IFN treatment, HBV DNA load, and ALT at baseline, PRELID2 
remained associated with the primary response (additive 
β = −0.67, SE = 0.16, odds ratio [OR] = 0.51, P = 3.70 × 10–5). 
PRELID2 was also associated with response at end of follow-up 
(P < .001, Figure 4), with sustained response (P = .001, Figure 4), 
and with combined HBeAg loss with HBV DNA <2000 IU/mL 
and ALT normalization (P < .001, Supplementary Materials) for 
HBeAg-positive patients.
For HBeAg-negative patients the most interesting top-hit SNP 
associated with the primary response was rs3821977 (β = 1.13, 
SE = 0.24, P = 2.46 × 10–6), which is located on chromosome 4, 
intronic within gene G3BP2, which has a function within the 
IFN pathway [25]. Response rates for best-guess genotypes were 
15%, 22%, and 49% for AA, AG, and GG, respectively (Figure 
4). In sensitivity analysis, this association remained strong after 
adjustment by the aforementioned variables. G3BP2 was also 
associated with sustained response, response at long-term fol-
low-up (Figure 4) and with combined HBV DNA <2000 IU/ml 
with ALT normalization (P < .001, Supplementary Materials).
PRELID2 Cross-validation in HBeAg-negative Patients
The association of PRELID2 rs371991 with response in HBeAg-
positive patients was further examined in HBeAg-negative 
patients. Here, we independently validated this association for 
HBeAg-negative patients at long-term follow-up (sustained 
response: AA vs AG vs GG: 32%, 26%, 19%; response at end of 
Figure 2. Q-Q plots for the complete cohort (A), HBeAg-positive patients (B) and HBeAg-negative patients (C). Abbreviation: HBeAg, hepatitis B e antigen.
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follow-up: 38%, 31%, 23%, P = .031 and P = .008, respectively, 
Figure 4). The association of G3BP2 with response in HBeAg-
negative patients could not be validated upstream the natural 
history in HBeAg-positive patients (P > .05).
G3BP2 Gene Function Shows a Differential Effect on IL-8, IP-10, and IL-10 
Protein Levels
Because G3BP2 rs3821977 is described as a factor within the IFN 
response pathway [25], we further focused on the consequence 
of the specific SNP genotype on the functionality of blood leu-
kocytes (cytokine production of predominantly monocytes and 
plasmacytoid dendritic cells) in response to exposure to IFN in 
healthy controls. The methods for this analysis can be found in 
the Supplementary Materials. In short, we genotyped healthy 
controls for the SNP and stimulated peripheral blood mononu-
clear cells (PBMCs) with IFN alone or in combination with R848 
(TLR7/8 ligand). Interleukin (IL)-8, IP-10, and IL-10 showed 
different trends between groups upon IFN+TLR7/8 stimula-
tion. Although IL-8 was higher in the GG than the AA group, 
IP-10 and IL-10 exhibited higher levels in the AA group (Figure 
5). For a subset of patients from the GWAS cohort, baseline 
IP-10 levels were available, which showed no differences across 
the G3BP2 genotypes pretreatment (P > .5). The results for the 
other cytokines and in relation to medium or IFNa alone, can be 
found in the Supplementary Materials.
DISCUSSION
In the current global investigator-initiated GWAS, we studied 
the largest (Peg)IFN treated CHB cohort to date, and identi-
fied TRAPPC9, PRELID2 and G3BP2 to be associated with 
both short and long-term response to (Peg)IFN. Although not 
genome-wide significant, these top-hit SNPs were suggestive 
of a meaningful association (P  <  10–6), across all ethnicities. 
Moreover, these SNPs were associated with, or were found 
within, different immune response pathways. If further corrob-
orated, this may have important implications for both the natu-
ral history of CHB and for current PegIFN therapy that should 
be individualized to patients with the highest likelihood of 
response. Furthermore, PegIFN is frequently used as an agent to 
decrease cccDNA and modify the immune response in studies 
on combination treatment, aiming for functional cure. The out-
come of this study may also help us to learn about the biology 
and likelihood of response to the many other new compounds 
in development to reach functional cure of CHB.
We performed in a large number of patients 3 GWAS: 1 for the 
complete group of CHB patients adjusted for HBeAg status, and also 
2 separate GWAS stratified by HBeAg. For HBeAg-positive patients, 
the main finding was the association of PRELID2 with (Peg)IFN 
response. This was observed for response at 24 weeks off-treatment, 
as well as sustained and long-term follow-up response. Further ver-
ifying this association, PRELID2 also showed an association with Ta
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sustained response in an independent cross-validation analysis of 
HBeAg-negative patients, suggesting this effect is preserved along 
the natural history of the disease. PRELID2 is known to downreg-
ulate STAT6. Located downstream the IL-4 receptor, lower lev-
els of STAT6 may impair T-helper cell differentiation and T-cell 
survival, which are known to be required processes for an effective 
HBV-specific T-cell response [26, 27]. This suggests a potential 
role for PRELID2 in CHB, likely via attenuating T-cell activity. To 
our knowledge, no other information is currently available on the 
involvement of PRELID2 in immune-mediated diseases.
Figure 3. Manhattan plots for the genome-wide association study for the complete cohort (A), HBeAg-positive patients, (B) and HBeAg-negative patients (C). Abbreviation: 
HBeAg, hepatitis B e antigen.
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Figure 4. PRELID2 and response for HBeAg-positive (A) and HBeAg-negative patients (B), and G3BP2 and response for HBeAg-negative patients (C). Abbreviation: HBeAg, 
hepatitis B e antigen; LTFU, long-term follow-up.
Another important finding of the current study that came 
from the GWAS in HBeAg-negative patients, were we found 
G3BP2 to have the strongest association with both short-term 
and long-term (Peg)IFN response. This gene has previously 
been associated with the IFN signaling response as antiviral 
mediator in the context of viral infection [25]. Therefore, we 
evaluated whether the SNP could recapitulate the observed 
association at the functional level. Overnight stimulation 
of PBMC of healthy controls showed lower protein levels of 
IL-10 and IP-10, and higher levels of IL-8 with the G3BP2 
response allele G.  IL-10 is a well-known immunoregulatory 
cytokine, which can downregulate T-cell immunity and has a 
significant role in viral resolution or persistence [26]. Lower 
levels of IL-10 observed with the G3BP2 G-allele could there-
fore be associated with a stronger IFN response. In contrast, 
earlier studies have shown a negative regulation by IL-8 on the 
IFNa antiviral response in an HCV system [28, 29], and it is 
therefore tempting to extrapolate these findings by suggesting 
that IL-8 may also influence IP-10 levels.
For the complete cohort, we found rs78900671, within gene 
COL22A1 and close to TRAPPC9, to have the strongest associ-
ation with response. TRAPPC9, also known as NIK and IKKβ 
binding protein (NIBP), functions as an enhancer of tumor 
necrosis factor α induced NFkB activation. NFkB is a multipo-
tent transcription factor, which is involved in many biological 
processes in (innate) immunity, inflammation and apoptosis 
[30]. Because it has a broad effect on multiple pathways, studies 
to decipher the functional consequences of the SNP genotype 
are difficult to perform and fall outside the scope of the current 
article. This should be further investigated in future studies.
The current study has been a long-term global investiga-
tor-initiated effort in which we have managed to gather the 
largest (Peg)IFN treated CHB cohort to date. Despite this fact, 
the Q-Q plots suggest that the study may be underpowered, and 
the genome-wide significance threshold could not be achieved. 
Nevertheless, we have found interesting genetic regions for 
further investigation. In addition, we have performed a power 
analysis prior to the study and aimed for at least 1000 patients 
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(see Supplementary Materials). However, because a GWAS is a 
genetic exploration and the magnitude of minor allele frequen-
cies and the effect of the gene cannot be predicted, we eventu-
ally included as many patients as possible.
Given the retrospective nature of our study, inevitably there 
is a potential of uncontrolled bias due to patient selection. One 
bias may be to include relatively more nonresponders because 
patients who achieve a durable response may be discharged and 
lost to follow-up. This was not the case for the current study. 
Patients not included in the GWAS (N = 637) were more often 
antiviral therapy experienced, collectively had a lower primary 
response rate (22%, vs 31% in the GWAS cohort, respectively), 
and had a similar response rate at end of follow-up of 25%. 
These percentages are in line with previous (Peg)IFN studies. 
Another potential caveat could be the heterogeneous popu-
lation, which could drive the findings in a GWAS if not con-
trolled for. To overcome this potential bias, our GWAS analysis 
was adjusted for the genetic ancestry principal components of 
the different populations in the analysis. Moreover, stratified by 
physician-reported ethnicity the associations remained compa-
rable (also see Supplementary Materials). This means that the 
findings from the current study are important for all reported 
ethnicities. For 30% of patients, we did not have information on 
HBsAg levels and for 50% not on HBV genotype, which are both 
important factors associated with response [23, 31–33]. Indeed, 
HBV genotype is also strongly related to ethnicity. Because we 
controlled for the genetic population stratification, chances of 
spurious genetic associations due to HBV genotypic differences 
driven by a possible overrepresentation of patients with a cer-
tain HBV genotype are highly unlikely but cannot be ruled out.
It is imperative to replicate findings discovered by a GWAS. 
For the current study we were able to cross-validate SNPs 
identified by the stratified GWAS. Importantly, here we inde-
pendently cross-validated PRELID2, found in HBeAg-positive 
patients, for an association with long-term (PEG)IFN response 
in HBeAg-negative patients. Not unexpectedly, we were not 
able to replicate G3BP2 in HBeAg-positive patients, because 
this was a significant SNP for HBeAg-negative patients. This is 
a genetically more selected subgroup, and it may not be possi-
ble to validate upstream the natural history of CHB. Therefore, 
we investigated the effect of the SNP on IFN responsiveness 
in healthy controls. Here we showed that G3BP2 differentially 
affects IP-10, IL-10, and IL-8 protein expression. A  poten-
tial influence of a CHB infection on the effect of the SNP in 
response to IFN could not be further investigated in the current 
study. The reason for this is that CHB patients in our clinics are 
Figure 5. Differential analytes detection for G3BP2 from supernatants of overnight stimulated PBMC with IFNa+R848 (TLR8 ligand). Abbreviations: IL, interleukin; IP, induc-
ible protein; PBMC, peripheral blood mononuclear cell.
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very heterogeneous in terms of age, phase of infection, antivi-
ral therapy use, and severity of liver disease. Moreover, there 
is a rather high frequency of Asian patients with a lower fre-
quency of the G3BP2 AA SNP. All of these factors likely affect 
the in vitro results and may mask the effect of the SNP on the 
responsiveness to IFN. Therefore, further studies investigating 
the function of G3BP2 should be performed in CHB patients.
In conclusion, we performed to our knowledge the first 
and largest GWAS study on (Peg)IFN treated CHB patients to 
date. We found genetic variations associated with response for 
HBeAg-positive and HBeAg-negative patients, irrespective of 
ethnicity, both when combined as well as in a stratified analy-
sis, and were able to further independently cross-validate these 
findings. If these results are further confirmed, this may have 
important clinical implications for further clinical guidance of 
patients both in the setting of the natural history, as well as for 
current or innovative immune modulating therapies.
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